Anavex Life Sciences Corp. (AVXL)

Market Cap	235.39M -64.1%
Revenue (ttm)	n/a
Net Income	-39.95M
EPS	-0.46
Shares Out	92.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	868,970
Open	2.650
Previous Close	2.620
Day's Range	2.475 - 2.730
52-Week Range	2.475 - 13.990
Beta	1.12
Analysts	Buy
Price Target	20.00 (+687.4%)
Earnings Date	Jun 22, 2026

About AVXL

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 34
• Stock Exchange: NASDAQ
• Ticker Symbol: AVXL
• Website: https://www.anavex.com

Analyst Summary

According to 2 analysts, the average rating for AVXL stock is "Buy." The 12-month stock price target is $20.0, which is an increase of 687.40% from the latest price.

Price Target

$20.0

(687.40% upside)

Analyst Consensus: Buy